Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback